CIPLA vs DRREDDY: Stock Comparison

CIPLA vs DR. REDDY S LABORATORIESUpdated 27 Aug 26, 4:08 PM ISTNSE & company filings

CIPLA is the larger company by market capitalisation. CIPLA shows a higher ROE, a higher dividend yield and faster revenue growth, while DR. REDDY S LABORATORIES shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

CIPLA leads 10; DRREDDY leads 3 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

CIPLADRREDDY

Valuation lens

What price are you paying?

Market CapContext only
₹1.14 L Cr
₹98,254 Cr
P/E RatioDRREDDY has the lower reading
34.03x
30.43x
P/B RatioDRREDDY has the lower reading
3.33x
2.59x
EPSCIPLA has the higher reading
₹10.67
₹4.85
Book ValueContext only
₹426.25
₹460.31
Dividend YieldCIPLA has the higher reading
0.91%
0.67%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹98,254 Cr
P/E Ratio
DRREDDY has a lower P/E
30.43x vs 34.03x
P/B Ratio
DRREDDY has a lower P/B
2.59x vs 3.33x
EPS
CIPLA has higher earnings per share
₹10.67 vs ₹4.85
Dividend Yield
CIPLA has a higher dividend yield
0.91% vs 0.67%
Revenue Growth (TTM YoY)
CIPLA has faster revenue growth
-2.1% vs -11.6%
EPS Growth (TTM YoY)
CIPLA has faster EPS growth
-54.6% vs -86.2%
Qtr Sales Growth
CIPLA has stronger quarterly sales growth
-28.68% vs -36.58%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLADRREDDY
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLADRREDDY
Live Price₹1,420₹1,177
Day Change1.23%-0.42%
Volume5.33 L10.44 L
52-Week High₹1,673₹1,414.9
52-Week Low₹1,165.7₹1,101
Distance from 52W High-15.12%-16.81%

Valuation

MetricCIPLADRREDDY
Market Cap₹1.14 L Cr₹98,254 Cr
P/E Ratio34.03x30.43x
P/B Ratio3.33x2.59x
EPS₹10.67₹4.85
Book Value₹426.25₹460.31
Dividend Yield0.91%0.67%

Growth

MetricCIPLADRREDDY
Revenue Growth (TTM YoY)-2.1%-11.6%
EPS Growth (TTM YoY)-54.6%-86.2%
Qtr Sales Growth-28.68%-36.58%
Qtr Profit Growth9.75%-7.09%

Profitability & Leverage

MetricCIPLADRREDDY
ROE11.19%10.27%
ROCE11.58%9.14%
Net Margin13.96%12.76%
Operating Margin18.74%21.43%
Debt to Equity0.01x0.17x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCIPLADRREDDY
Promoter Holding9.17%26.64% 0.01 pp
FII Holding20.21% 2.35 pp32.07% 1.01 pp
DII Holding34.63% 2.66 pp31.74% 1.02 pp
Public Holding15.94% 0.31 pp9.35% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CIPLA and DR. REDDY S LABORATORIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.